Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced today the launch of an authorized generic of Victoza ® 1, in the United States. "By launching an ...

Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the ...

Teva Pharmaceuticals has received FDA approval and has launched a generic version of Saxenda (liraglutide), which is approved to treat adults and adolescents 12 to 17 years of age who are obese or ...

The FDA approved the first-ever generic form of a GLP-1 receptor agonist specifically indicated for weight loss, Teva ...

Teva Pharmaceuticals gained FDA approval to launch the first generic GLP-1 drug for weight loss, a liraglutide injection based on Saxenda.

The FDA today approved the first generic referencing the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide (Victoza), an 18 mg/3 mL injection, to improve glycemic control in patients ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best strong buy growth stocks to buy now. On August 28, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced the FDA approval ...

The FDA has approved the first generic liraglutide indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes.

Liraglutide Weight Loss Injections Liraglutide is the active ingredient in Saxenda and Victoza. Like Ozempic and Wegovy, liraglutide is an injected GLP-1 receptor agonist that can suppress ...

Teva Pharmaceuticals announced in late August 2025 that it received FDA approval and commenced the U.S. launch of its generic version of Saxenda® (liraglutide injection), which had annual sales of ...

One difference is that liraglutide weight loss injections are injected once daily as opposed to weekly. Saxenda is FDA-approved for weight management in people with obesity.

The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve ...